Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
NovaBridge Biosciences American Depositary Shares represent ownership in NovaBridge Biosciences, a biotechnology company founded in 2020 and headquartered in Shanghai, China. The company specializes in developing innovative precision therapies for oncology and immunology indications. Its primary focus centers on next-generation antibody-drug conjugates (ADCs), bispecific antibodies, and protein degraders designed to target difficult-to-treat cancers and autoimmune diseases. NovaBridge Biosciences leverages advanced platforms, including proprietary linker-payload technologies and tumor-targeted delivery systems, to create therapeutics with enhanced efficacy and reduced toxicity profiles. The company advances its pipeline through discovery, preclinical development, and clinical-stage programs, partnering with global pharmaceutical firms to accelerate innovation. These American Depositary Shares enable U.S. investors to access NovaBridge's biotechnology portfolio, which plays a key role in addressing unmet medical needs in the rapidly evolving biopharma sector focused on immuno-oncology and immune modulation.
$1.80
$0.06 (-3.23%)
EOD Jul 14, 2026
ROIC dropped from -19.32% to -33.92%, capital efficiency is deteriorating. Negative free cash flow of -$21M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$88M
▼ -297.4% YoY
Op. Margin
—
ROIC
-33.92%
▼ -14.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$21M
▲ +60.9% YoY
Op. Cash Flow (TTM)
-$21M
▲ +47.2% YoY
Net Debt
-$208M
Net Cash Position
Cash & Equiv.
$211M
Continue Research
NovaBridge Biosciences American (NBP)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, NovaBridge Biosciences American scores 18/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
NovaBridge Biosciences American scores 18 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -33.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh NBP's valuation and scores 18/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.